glp-1 agonists diabetes The Unstoppable Rise of Agonists: Revolutionising and Obesity Treatment Glucagon‐like peptide‐1 receptor agonist (GLP‐1RA)

1 In parallel, semaglutide will become generic in some key markets from 2026 onward (e.g., India, China, Brazil), and pressure from compounding pharmacies to meet unmet demand for GLP1 therapies adds another layer of complexity and competition to the evolving treatment landscape

GLP-1R has been detected in healthy thyroid cells other than C cells, as well as in some papillary thyroid cancers (75)

Jeibmann, A., Alves, M., Rago, V., et al

These recommendations can enable healthcare professionals (HCPs) to better guide GLP-1 RA users toward lasting health improvements

The GLP-1 receptor agonist market is growing rapidly, supported by rising obesity and diabetes prevalence, strong clinical outcomes, and increasing patient awareness

Stopping Ozempic three to seven days prior to surgery was an independent risk factor for conversion to intubation, while the 14-day and 30-day cohorts had no independent risk factor for this complication